| Literature DB >> 25943469 |
Roselinde Kessels1, Pieter Van Herck2, Eline Dancet3,4,5, Lieven Annemans6, Walter Sermeus7.
Abstract
BACKGROUND: Many developed countries are reforming healthcare payment systems in order to limit costs and improve clinical outcomes. Knowledge on how different groups of professional stakeholders trade off the merits and downsides of healthcare payment systems is limited.Entities:
Mesh:
Year: 2015 PMID: 25943469 PMCID: PMC4465730 DOI: 10.1186/s12913-015-0847-7
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Healthcare system performance objectives or domains considered to be relevant to assess care payment system effects
|
|
|
|---|---|
|
| The degree to which the level of health gain is maximized and harm to patients is minimized as a consequence of care. This domain refers to the effect of the payment scheme, and its sustainability, on patient outcome in a broad sense (life expectancy, relief of pain, functional capacity, etc.). |
|
| The degree to which services are provided based on scientific knowledge to all who could benefit (avoiding underuse) and are refrained from being provided to those not likely to benefit (avoiding overuse). This implies that (1) patients do not receive care that cannot help them and/or the risks of which outweigh the benefits and (2) patients reliably receive care where the known benefits outweigh the risks. |
|
| The degree to which care and its optimal outcome are delivered and attained for all people, without variation based on patient characteristics (such as gender, age, ethnicity, geographical location and socioeconomic status), unless there is a valid clinical rationale. |
|
| The degree to which provider contributions are well integrated to optimize the delivery of care by the same healthcare provider throughout the course of care, with appropriate and timely communication, referral and collaboration between providers (both within and between provider organizations). |
|
| The degree to which care is respectful of and responsive to individual patient preferences and values, ensuring that patient preferences and values guide major clinical decisions. |
|
| The degree to which waits and delays are avoided. |
|
| The degree to which expenditure of financial resources is contained in short term. Short term expenditure may not only be due to cost of care (including potential waste), but also due to investment in system organization (e.g. cost of implementation). |
|
| The degree to which expenditure of financial resources is contained in long term. Long term expenditure may not only be due to cost of care (including potential waste), but also due to maintenance of system organization (e.g. cost of measuring and updating). |
|
| The degree to which provider wellness is sustained, improves or deteriorates, as affected by job satisfaction, income (in)security, workload, autonomy and respect of professional values. |
|
| The degree to which innovation of care, at the clinical treatment and/or organizational system level, is encouraged. This includes the strategy and investment focus of the provider (e.g. on quality vs. quantity). |
|
| The degree to which providers consciously or unconsciously manipulate the system to increase personal financial gain. Gaming includes both data manipulation and/or patient selection (shifting care for high expenditure patients to other providers or providing less than appropriate care). |
Figure 1Example of a discrete choice task.
Characteristics of the 547 respondents in the study
|
|
|
|---|---|
| Age | 50 ± 11 years* |
| Seniority | 23 ± 11 years* |
| Female sex | 31% |
|
| |
| Physician | 67% |
| Policy maker | 22% |
| Healthcare executive | 34% |
| Researcher | 30% |
|
| |
| Medicine | 69% |
| Nursing | 3% |
| Allied health | 6% |
| Policy | 17% |
| Executive management | 17% |
| Financial management | 8% |
| Public health | 10% |
| Quality of care | 17% |
| Health economics | 13% |
| Psychology | 2% |
| Social sciences | 3% |
| Human resource management | 4% |
| Law | 5% |
| Ethics | 4% |
| Insurance | 5% |
| Pharmacy | 3% |
|
| |
| Canada | 10% |
| Eastern Europe | 9% |
| Western Europe | 25% |
| Oceania | 18% |
| United States of America | 37% |
|
| |
| Solo primary care | 13% |
| Group primary care | 19% |
| Non-teaching hospital | 8% |
| Teaching hospital | 34% |
|
| |
| Salary | 67% |
| Fee for service | 60% |
| Episode-based | 6% |
| Capitation | 16% |
| Quality bonus or adjustment | 16% |
| Evidence informed case rate | 2% |
| Never event non-reimbursement/warranty | 1% |
*The ± values are means ± SD.
°Respondents could select more than one response category.
§These characteristics pertain to physicians only.
Figure 2Importance of the eleven healthcare performance objectives or domains in the MNL model relative to the most important objective ‘effectiveness and patient safety’.
Figure 3Marginal utility values (main effects) of the positive, negative and status quo outcomes related to the eleven healthcare performance objectives.
Figure 4Marginal utility values of the positive, negative and status quo outcomes showing significant differences in preference evaluation between physicians and non-physicians.
Figure 5Marginal utility values of the positive, negative and status quo outcomes showing significant differences in preference evaluation between geographical areas.
Predicted total utility by stakeholder group, before and after proposed payment reform
|
|
|
|
|
|
|---|---|---|---|---|
| Canada | Physician | 0.61 | 0.48 | −0.21 |
| Policy maker | −0.04 | 0.82 | 21.50 | |
| Healthcare executive | 0.37 | 0.48 | 0.30 | |
| Researcher | 0.42 | 1.18 | 1.81 | |
| Oceania | Physician | 1.57 | 1.18 | −0.25 |
| Policy maker | 0.92 | 1.52 | 0.65 | |
| Healthcare executive | 1.33 | 1.18 | −0.11 | |
| Researcher | 1.38 | 1.88 | 0.36 | |
| Eastern Europe | Physician | 0.22 | 1.40 | 5.36 |
| Policy maker | −0.43 | 1.74 | 4.05 | |
| Healthcare executive | −0.02 | 1.40 | 70.00 | |
| Researcher | 0.03 | 2.10 | 69.00 | |
| Western Europe | Physician | 0.96 | 0.80 | −0.17 |
| Policy maker | 0.31 | 1.14 | 2.68 | |
| Healthcare executive | 0.72 | 0.80 | 0.11 | |
| Researcher | 0.77 | 1.50 | 0.95 | |
| United States | Physician | 1.00 | 1.23 | 0.23 |
| Policy maker | 0.35 | 1.57 | 3.49 | |
| Healthcare executive | 0.76 | 1.23 | 0.62 | |
| Researcher | 0.81 | 1.93 | 1.38 |
*Relative difference is the difference between the total utility after proposed payment reform and the total utility of the status quo, expressed relatively to the total utility of the status quo.
Survey 1 of the Bayesian D-optimal partial profile design
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | * | * | * | + | N | + | – | * | * | – |
|
| * | * | * | * | N | – | – | + | * | * | N |
|
| * | * | – | * | * | – | * | + | – | N | * |
|
| * | * | + | * | * | N | * | N | N | – | * |
|
| * | * | – | * | * | + | N | + | N | * | * |
|
| * | * | + | * | * | N | + | – | – | * | * |
|
| * | * | N | + | * | – | * | – | * | + | * |
|
| * | * | – | N | * | + | * | N | * | – | * |
|
| * | – | * | * | § | § | * | * | * | N | + |
|
| * | N | * | * | § | § | * | * | * | + | – |
|
| * | N | * | § | – | * | N | + | * | * | * |
|
| * | – | * | § | N | * | – | – | * | * | * |
|
| * | – | * | * | N | + | * | * | * | – | – |
|
| * | N | * | * | – | N | * | * | * | N | + |
|
| * | N | § | – | – | * | * | * | N | * | * |
|
| * | – | § | N | N | * | * | * | – | * | * |
|
| * | + | N | * | + | * | N | * | * | + | * |
|
| * | N | + | * | N | * | – | * | * | – | * |
|
| N | * | * | § | * | * | + | + | § | * | * |
|
| – | * | * | § | * | * | – | N | § | * | * |
|
| N | * | * | * | * | + | – | – | – | * | * |
|
| + | * | * | * | * | – | + | N | + | * | * |
|
| + | * | * | * | N | * | * | N | N | * | – |
|
| – | * | * | * | + | * | * | – | + | * | N |
|
| N | * | * | * | + | – | * | * | * | N | – |
|
| + | * | * | * | N | N | * | * | * | + | N |
|
| + | * | * | N | * | + | * | * | – | * | N |
|
| – | * | * | – | * | N | * | * | + | * | + |
|
| + | * | * | – | * | * | N | – | * | + | * |
|
| – | * | * | + | * | * | – | + | * | – | * |
|
| – | * | – | * | N | * | + | * | * | * | N |
|
| + | * | + | * | – | * | – | * | * | * | + |
|
| – | + | – | * | * | * | – | * | * | * | + |
|
| + | N | + | * | * | * | N | * | * | * | N |
|
| N | – | + | N | * | * | N | * | * | * | * |
|
| – | N | N | – | * | * | + | * | * | * | * |
Survey 2 of the Bayesian D-optimal partial profile design
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | * | * | * | + | § | – | * | – | * | N |
|
| * | * | * | * | N | § | N | * | N | * | – |
|
| * | * | * | * | – | N | § | N | § | * | * |
|
| * | * | * | * | N | – | § | + | § | * | * |
|
| * | * | * | + | – | § | * | * | + | * | – |
|
| * | * | * | – | N | § | * | * | N | * | + |
|
| * | * | * | N | N | * | * | N | * | N | N |
|
| * | * | * | + | + | * | * | + | * | – | – |
|
| * | * | – | N | * | * | * | * | N | + | – |
|
| * | * | + | – | * | * | * | * | + | – | N |
|
| * | * | + | + | * | * | N | * | * | – | N |
|
| * | * | N | N | * | * | – | * | * | + | – |
|
| * | N | * | * | + | * | * | N | + | – | * |
|
| * | – | * | * | – | * | * | + | – | N | * |
|
| * | – | * | * | – | + | + | * | * | * | N |
|
| * | + | * | * | N | – | N | * | * | * | – |
|
| * | – | * | + | * | * | * | – | N | * | + |
|
| * | + | * | – | * | * | * | + | + | * | – |
|
| * | N | § | + | § | * | – | * | * | * | * |
|
| * | – | § | – | § | * | + | * | * | * | * |
|
| * | N | N | * | * | + | * | * | * | – | + |
|
| * | – | – | * | * | N | * | * | * | + | – |
|
| * | – | N | * | * | N | * | + | * | * | + |
|
| * | + | – | * | * | – | * | – | * | * | N |
|
| + | * | § | § | * | * | – | * | * | N | * |
|
| N | * | § | § | * | * | + | * | * | + | * |
|
| N | * | * | * | N | N | – | N | * | * | * |
|
| + | * | * | * | – | + | + | – | * | * | * |
|
| N | N | * | * | * | * | N | * | – | + | * |
|
| + | – | * | * | * | * | + | * | + | N | * |
|
| – | + | * | N | * | * | * | * | – | – | * |
|
| N | N | * | – | * | * | * | * | + | N | * |
|
| N | + | – | § | * | N | * | * | * | * | * |
|
| + | N | N | § | * | + | * | * | * | * | * |
|
| + | – | – | * | – | * | * | * | * | + | * |
|
| – | + | + | * | N | * | * | * | * | – | * |
Survey 3 of the Bayesian D-optimal partial profile design
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * | * | + | * | * | § | + | § | * | § | * |
|
| * | * | N | * | * | § | – | § | * | § | * |
|
| * | * | + | * | * | * | – | N | – | + | * |
|
| * | * | N | * | * | * | + | – | N | – | * |
|
| * | * | + | § | * | + | * | * | § | + | * |
|
| * | * | – | § | * | – | * | * | § | N | * |
|
| * | * | – | * | N | * | + | * | N | * | + |
|
| * | * | + | * | + | * | N | * | – | * | – |
|
| * | – | * | * | * | N | + | * | N | – | * |
|
| * | N | * | * | * | + | N | * | – | + | * |
|
| * | + | * | + | * | + | * | N | * | * | – |
|
| * | – | * | N | * | – | * | + | * | * | N |
|
| * | N | * | – | – | * | + | N | * | * | * |
|
| * | – | * | + | N | * | N | + | * | * | * |
|
| * | N | N | * | N | * | * | + | – | * | * |
|
| * | + | + | * | + | * | * | N | N | * | * |
|
| – | * | * | * | * | * | * | + | N | N | N |
|
| + | * | * | * | * | * | * | N | + | – | – |
|
| – | * | * | § | * | – | + | * | * | * | + |
|
| + | * | * | § | * | + | – | * | * | * | N |
|
| – | * | § | N | N | * | * | * | N | * | * |
|
| + | * | § | + | + | * | * | * | + | * | * |
|
| – | * | * | N | + | * | * | N | * | N | * |
|
| + | * | * | – | N | * | * | + | * | + | * |
|
| + | * | * | + | – | N | * | * | * | – | * |
|
| N | * | * | N | N | – | * | * | * | + | * |
|
| – | * | + | – | * | + | * | * | * | * | + |
|
| + | * | N | + | * | – | * | * | * | * | N |
|
| + | – | * | * | * | * | * | N | * | – | + |
|
| N | + | * | * | * | * | * | – | * | + | N |
|
| N | – | * | + | * | + | * | * | N | * | * |
|
| – | N | * | N | * | N | * | * | + | * | * |
|
| – | + | + | * | * | * | * | N | * | * | – |
|
| N | – | N | * | * | * | * | – | * | * | + |
|
| – | – | N | * | + | * | * | * | N | * | * |
|
| N | + | + | * | N | * | * | * | – | * | * |
A priori order of importance of the main effects of the eleven performance domains and conversion into mean utility values and variances for the multivariate normal prior distribution
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
|
| |||
| 1 | Clinical effectiveness and patient safety | −0.6 | 0.1 | 0.5 | 0.09 |
| 2 | Best practice service use | −0.4 | 0.05 | 0.35 | 0.06 |
| Long term cost containment and budget safety | −0.4 | 0.05 | 0.35 | 0.06 | |
| 3 | Gaming the system | −0.35 | 0.05 | 0.3 | 0.04 |
| Care equity | −0.35 | 0.05 | 0.3 | 0.04 | |
| Care coordination, teamwork and continuity | −0.35 | 0.05 | 0.3 | 0.04 | |
| 4 | Timeliness | −0.3 | 0.05 | 0.25 | 0.02 |
| Patient centeredness | −0.3 | 0.05 | 0.25 | 0.02 | |
| Innovation | −0.3 | 0.05 | 0.25 | 0.02 | |
| Provider wellness | −0.3 | 0.05 | 0.25 | 0.02 | |
| Short term cost containment and budget safety | −0.3 | 0.05 | 0.25 | 0.02 | |
The mean values are associated with the negative (–), neutral (N) and positive (+) outcomes in each performance domain. Variances around the mean values are the same for all three outcomes in a performance domain and are therefore listed only once.